StreetInsider.com News Articles

PharmaCorp to Present as Planet Microcap Toronto 2026 Conference

Wed, 21 Oct 2026 11:36:00 -0400

SASKATOON, Saskatchewan, Oct. 21, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform, announced today that senior management will present at the Planet MicroCap Toronto 2026 Conference (the “Conference”) at the Arcadian Loft in Toronto on Wednesday, October 28, 2026, at 5:30 P.M. Eastern Time.

Management will also be available to host in-person meetings with registered attendees during the Conference on October 28th and October 29th.

Interested parties can view the live and archived webcast of PharmaCorp’s presentation via the following webcast

PharmaCorp to Present as Planet Microcap Toronto 2026 Conference

Wed, 21 Oct 2026 11:36:00 -0400

Management will also be available to host in-person meetings with registered attendees during the Conference on October 28th and October 29th.

Interested parties can view the live and archived webcast of PharmaCorp’s presentation via the following webcast

PharmaCorp names Andrew Hodson as CFO, replacing retiring Terri Tatchell

Wed, 14 Oct 2026 07:30:24 -0400

PharmaCorp Rx Inc. (TSXV: PCRX) announced that Andrew Hodson will join the company as Chief Financial Officer on October 27, 2026, succeeding Terri Tatchell, who will retire from the role on the same date.

Tatchell will remain with the Saskatoon, Saskatchewan-based company for three months as a consultant to assist with the transition of CFO responsibilities.

Hodson brings more than 11 years of financial leadership experience, including over six years leading global finance teams in high-growth and acquisition-driven businesses. Most recently, he served as Head of Finance for Marshall Land Systems Ltd., where he oversaw financial reporting across Canadian and UK entities.

Prior

PharmaCorp Announces CFO Transition and Appointment of Andrew Hodson as Chief Financial Officer

Wed, 14 Oct 2026 07:30:00 -0400

New CFO Andrew Hodson brings to PharmaCorp more than 11 years of financial leadership, including capital markets experience and over six years leading global finance teams in high-growth and acquisition-driven businesses

SASKATOON, Saskatchewan, Oct. 14, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform, announced today that Andrew Hodson will join the Corporation effective October 27, 2026, as its Chief Financial Officer.

Mr. Hodson will succeed current CFO Terri Tatchell, who will retire from the role on the same date.

PharmaCorp Announces CFO Transition and Appointment of Andrew Hodson as Chief Financial Officer

Wed, 14 Oct 2026 07:30:00 -0400

New CFO Andrew Hodson brings to PharmaCorp more than 11 years of financial leadership, including capital markets experience and over six years leading global finance teams in high-growth and acquisition-driven businesses

Mr. Hodson will succeed current CFO Terri Tatchell, who will retire from the role on the same date.

Form SCHEDULE 13D/A Pacira BioSciences, Inc. Filed by: Doma Perpetual Capital Management LLC

Tue, 13 Oct 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20261013/27182117.html

Form 4 Pacira BioSciences, Inc. For: Oct 08 Filed by: RIKER LAUREN

Fri, 09 Oct 2026 19:08:00 -0400

si-local-file:///var/storage/secattach/20261009/27172516.html

H.C. Wainwright Downgrades Pacira Pharmaceuticals (PCRX) to Neutral

Fri, 09 Oct 2026 06:14:19 -0400

H.C. Wainwright analyst Douglas Tsao downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Neutral with a price target of $36.50.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $36.39 yesterday.

Form SC TO-C Pacira BioSciences, Inc. Filed by: Viatris Inc

Thu, 08 Oct 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20261008/27167511.html

Form SC14D9C Pacira BioSciences, Inc. Filed by: Pacira BioSciences, Inc.

Thu, 08 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261008/27167175.html

Pacira Pharmaceuticals (PCRX) PT Raised to $36.50 at RBC Capital

Thu, 08 Oct 2026 14:09:10 -0400

RBC Capital analyst Gregory Renza raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $36.50 (from $25.00) while maintaining a Sector Perform rating.

Oppenheimer Downgrades Pacira Pharmaceuticals (PCRX) to Perform

Thu, 08 Oct 2026 13:26:00 -0400

Oppenheimer analyst Les Sulewski downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Outperform to Perform.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $25.20 yesterday.

Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold

Thu, 08 Oct 2026 12:37:57 -0400

Jefferies analyst Glen Santangelo downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $36.00.

The analyst comments "VTRS announced it will acquire PCRX for $1.65B. This is (+) for PCRX but more mixed for VTRS. The deal will be accretive to EBITDA + good synergies w/ meloxicam. But we'd watch out for: (1) Exparel going generic in 2030 (volume limited), but there are 2 PIV filers w/ litigation ongoing. Base case is for moderate erosion beyond 2030, but mgmt still see sig value beyond 2030. (2) NO-PAIN expires Dec 2027 and needs to be renewed. Downgrade

Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold

Thu, 08 Oct 2026 12:37:57 -0400

Jefferies analyst Glen Santangelo downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $36.00.

Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold

Thu, 08 Oct 2026 12:37:57 -0400

Jefferies analyst Glen Santangelo downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $36.00.

Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold

Thu, 08 Oct 2026 12:37:57 -0400

Jefferies analyst Glen Santangelo downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $36.00.

Needham Downgrades Pacira Pharmaceuticals (PCRX) to Hold

Thu, 08 Oct 2026 12:18:51 -0400

Needham analyst Serge Belanger downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $25.20 yesterday.

JPMorgan Upgrades Pacira Pharmaceuticals (PCRX) to Neutral

Thu, 08 Oct 2026 12:18:34 -0400

JPMorgan analyst Hardik Parikh upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Underweight to Neutral.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $25.20 yesterday.

Form 144 Pacira BioSciences, Inc. Filed by: RIKER LAUREN

Thu, 08 Oct 2026 10:02:00 -0400

si-local-file:///var/storage/secattach/20261008/27165213.html

Form 8-K Pacira BioSciences, Inc. For: Oct 08

Thu, 08 Oct 2026 09:25:00 -0400

si-local-file:///var/storage/secattach/20261008/27164911.html

Form SC TO-C Pacira BioSciences, Inc. Filed by: Viatris Inc

Thu, 08 Oct 2026 08:46:00 -0400

si-local-file:///var/storage/secattach/20261008/27164475.html

Viatris to acquire Pacira BioSciences for $1.65 billion

Thu, 08 Oct 2026 07:45:31 -0400

Viatris Inc. (NASDAQ: VTRS) has agreed to acquire Pacira BioSciences, Inc. (NASDAQ: PCRX) for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion, according to a joint press release from the two companies.

The transaction, unanimously approved by the boards of both companies, will be structured as a tender offer for all outstanding shares of Pacira common stock. Any shares not tendered will be acquired through a second-step merger at the same price. The deal is expected to close by the end of 2026, subject to customary closing conditions including a majority tender of Pacira shares and

Viatris to acquire Pacira BioSciences for $1.65 billion

Thu, 08 Oct 2026 07:45:31 -0400

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Thu, 08 Oct 2026 07:45:00 -0400

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure
Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Thu, 08 Oct 2026 07:45:00 -0400

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure
Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities